Cancer Gene Therapy (Delivery)

HUVEC Used as a Cellular Vehicle for Gene Therapy

Published in Gene Therapy Weekly, November 3rd, 1997

HSVtk/GCV suicide gene therapy has a new cellular vehicle for gene product delivery: human umbilical endothelial vein cells (HUVEC) have been successfully used to deliver toxic gene products to tumor cells in vivo.

Researchers C. Rancourt and colleagues from the University of Alabama, Birmingham, Alabama, examined the feasibility of using HUVEC as vehicles for delivery toxin gene products to tumor sites. They presented in vitro and in vivo results at the 3rd European Conference on Gene Therapy of Cancer, held September 11-13, 1997, in Berlin, Germany ("Human Endothelial Cells as Cellular Vehicles for Ovarian Cancer Gene Therapy").

After initially...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1997-11-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry